US Food and Drug Administration Approval Summary: Ribociclib With an Aromatase Inhibitor in the Adjuvant Hormone Receptor–Positive, Human Epidermal Growth Factor Receptor 2–Negative Stage II and III ...

The BREAKWATER trial demonstrated the efficacy of a BRAF-targeted regimen using FOLFIRI, offering a neuropathy-free option for metastatic colorectal cancer patients. HERIZON-GEA-01 trial results ...

Experts highlight key themes from the ASCO GI Cancers Symposium, including the growing role of AI and an increased emphasis on patient-centered decision-making. During the 2026 ASCO Gastrointestinal ...

Presenters shared their personal highlights of attending ASCO GI 2026. The 2026 American Society of Clinical Oncology (ASCO) Gastrointestinal (GI) Cancers Symposium showcased not only transformative ...

ASCO Guidelines provide recommendations with comprehensive review and analyses of the relevant literature for each recommendation, following the guideline development process as outlined in the ASCO ...

The guideline update included 26 specific recommendations grouped in the overarching topics of discussions about infertility risk, risk for infertility with anticancer treatment, FP for men, FP for ...

Reporting on studies in early breast cancer presented at ASCO 2025, Dr Ian Krop of Yale Cancer Center discusses potential refinements in treatment across all subtypes as well as a significant study in ...

Bispecific antibodies are one of the most active areas of cancer research, and pharmaceutical companies are busy striking deals to add them to their pipelines. One of the most talked about drugs at ...

Prior to the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting, I put together a preview article focused on the biotech-related stories coming out of the various oral presentations at ...

Leaders in oncology share why the American Society of Clinical Oncology (ASCO) meeting remains a top global gathering for breakthroughs, networking, and lifelong learning. Oncology professionals ...

With the American Society of Clinical Oncology (ASCO) annual meeting in full swing at Chicago’s McCormick Place this past weekend, Johnson & Johnson and its latest lung cancer campaign towered high ...